Jim Cramer built a case for how infrastructure spending could impact this materials company’s earnings. » Read More
Discussing activist investor activity in Darden and the performance of the fast casual dining space, with David Palmer, RBC Capital Markets.
Discussing if recent economic growth will drive the Fed to lift its economic timetable, with David Kelly, JPMorgan Funds chief global strategist, and Lindsey Piegza, Sterne Agee chief economist.
CNBC contributor Jim Iuorio reports the latest data on business inventories.
Jim Iuorio of TJM Institutional Services, reports Friday's good consumer sentiment number.
CNBC's Bob Pisani looks at the real problem for commodities right now, and the weakness in Chinese Internet stocks this week.
CNBC's Jim Cramer explains his next generation pharma plays, and why he really likes Isis Pharmaceuticals.
CNBC's Kayla Tausche reports Alibaba's bankers are planning on closing its books early, and demand is strong enough to price above its current range. Jim Cramer provides insight on the deal.
CNBC's Jim Cramer discusses Apple's product presentation and why the stock went down after launch.
CNBC's David Faber and Jim Cramer discuss the influence of activist investors on corporate America as Hertz and Darden come under pressure from Carl Icahn and Starboard Value.
Richard Bernstein, Richard Bernstein Advisors, and Jeffrey Saut, Raymond James, share their thoughts on market valuations.
The retail sales report, released at 8:30 a.m. ET, is the most important data point since last Friday's disappointing jobs report.
Mad Money host Jim Cramer explains how new wearable technology for law enforcement officers could take Taser higher.
Headlines hiding investing opportunities? Mad Money's Jim Cramer dissects today's market action and sounds off on politics in Washington.
Michael Small, Gogo CEO and president, discusses its mission to engage passengers on an aircraft with connectivity solutions.
Donald Trump Jr., The Trump Organization's executive vice president, says starving demand is fueling high-end luxury in the emerging markets.
Andy Hargreaves, Pac Crest, explains why Apple's product announcement didn't provide any new profit drivers for the company.
CNBC's Mary Thompson reports live from Cantor Fitzgerald's 4th annual Charity Day.
Shares of biotech company Orexigen sunk today despite the FDA approval of its obesity drug. CNBC's Meg Tirrell dissects the move.
CNBC's Dominic Chu looks at where the strongest buying has come after stocks pull back. CNBC contributor Jon Najarian and Tom Joyce, Knight Capital, weigh in on those best performing sectors.
Dennis Gartman of the Gartman Letter, dissects crude oil's reversal today and how gold impacts commodity prices.